Vitalina I. Maiborodina

Vitalina I. Maiborodina

Auto-generated profile, based on publicly available information

Vitalina I. Maiborodina

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
IMIgor Maiborodin
Igor Maiborodin
GYGennadiy Yarin
Gennadiy Yarin
SMSergey Marchukov
Sergey Marchukov
AUAlexandra Uzyumova
Alexandra Uzyumova
GLGalina Anatolievna Lapii
Galina Anatolievna Lapii
VMVitalina Maiborodina
Vitalina Maiborodina
The scientific literature of recent years contains a lot of data about using multipotent stromal cells (MSCs) for urinary incontinence correction. Despite this, the ideal treatment method for urinary incontinence has not yet been created. The cell therapy results in patients and experimental animals with incontinence have shown promising results, but the procedures require further optimization, and more research is needed to focus on the clinical phase. The MSC use appears to be a feasible, safe, and effective method of treatment for patients with urinary incontinence. However, the best mode for application of cell technology is still under study. Most clinical investigations have been performed on only a few patients and during rather short follow-up periods, which, together with an incomplete knowledge of the mechanisms of MSC action, does not make it possible for their widespread implementation. The technical details regarding the MSC application remain to be identified in more rigorous preclinical and clinical trials.

25 August 2020 in Novosti Khirurgii
Verified
Journal Article
Closed access
IMIgor Maiborodin
Igor Maiborodin
SMS.V. Marchukov
S.V. Marchukov
VMV.V. Morozov
V.V. Morozov
VMV.A. Matveeva
V.A. Matveeva
VMV.I. Maiborodina
V.I. Maiborodina
ASAndrey Ivanovich Shevela
Andrey Ivanovich Shevela

1 April 2021 in Life
Verified
Journal Article
Open access
PDF file
IMIgor Maiborodin
Igor Maiborodin
ASAleksandr Shevela
Aleksandr Shevela
MTMichael Toder
Michael Toder
SMSergey Marchukov
Sergey Marchukov
NTNatalya Tursunova
Natalya Tursunova
ASAndrey Ivanovich Shevela
Andrey Ivanovich Shevela
When administered intravenously, extracellular vesicles derived from multipotent stromal cells (MSC EVs) immediately pass through the lungs along with the blood and regularly spread to all organs. When administered intraperitoneally, they are absorbed either into the blood or into the lymph and are quickly disseminated throughout the body. The possibility of generalized spread of MSC EVs to distant organs in case of local intratissular administration remains unexplored. However, it is impossible to exclude MSC EV influence on tissues distant from the injection site due to the active or passive migration of these injected nanoparticles through the vessels. The research is based on findings obtained when studying the samples of lungs, heart, spleen, and liver of outbred rabbits of both sexes weighing 3–4 kg at various times after the injection of EVs derived from MSCs of bone marrow origin and labeled by PKH26 into an artificially created defect of the proximal condyle of the tibia. MSC EVs were isolated by serial ultracentrifugation and characterized by transmission electron microscopy and flow cytometry. After the introduction of MSC EVs into the damaged proximal condyle of the tibia of rabbits, these MSC EVs can be found most frequently in the lungs, myocardium, liver, and spleen. MSC EVs enter all of these organs with the blood flow. The lungs contained the maximum number of labeled MSC EVs; moreover, they were often associated with detritus and were located in the lumen of the alveoli. In the capillary network of various organs except the myocardium, MSC EVs are adsorbed by paravasal phagocytes; in some cases, specifically labeled small dust-like objects can be detected throughout the entire experiment—up to ten days of observation. Therefore, we can conclude that the entire body, including distant organs, is effected both by antigenic detritus, which appeared in the bloodstream after extensive surgery, and MSC EVs introduced from the outside.

15 November 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
IMIgor Maiborodin
Igor Maiborodin
MKMarina Klinnikova
Marina Klinnikova
SKSergey Kuzkin
Sergey Kuzkin
VMVitalina Maiborodina
Vitalina Maiborodina
SKSergey Krasil’nikov
Sergey Krasil’nikov
ELElena Lushnikova
Elena Lushnikova
The effect of extracellular vesicles (EVs) of various origins on the heart structures in the time of health and disease has been well studied. At the same time, data on the distribution of EVs throughout the body after introduction into the tissues and the possibility of the influence of these EVs on organs distant from the injection site are practically absent. It is also necessary to note a certain inconsistency in the results of various researchers: from articles on the direct absorption of EVs derived from mesenchymal multipotent stromal cells (MSC EVs) by cardiomyocytes to the data that the heart is inherently immune to drug delivery mediated by nanoparticles. In this regard, the morphological changes in the myocardium of outbred rabbits of both sexes weighing 3–4 kg were studied at various times after experimental trauma of the bone tissue in the proximal condyle of the tibia (PCT) and the use of MSC EVs. As a result of modeling the PCT defect, rabbits develop myocardial edema in the heart muscle by the 3rd day, their lymphatic vessels expand, and then, on the 7th day, the blood vessels become dilated. In the myocardium, the relative and absolute contents of neutrophils, erythrocytes, and macrophages increase, but the percentage of lymphocytes decreases. By day 10, almost all of these changes return to their initial values. The detected transformations of the myocardium are most likely due to the ingress of detritus with the blood flow from the PCT. The use of MSC EVs to influence the regeneration of damaged tissue of PCT promotes earlier dilatation of the blood vessels of the heart with pronounced diapedesis of erythrocytes or even hemorrhages, prolongation of edema, the formation of blood clots in vessels with obliteration of their lumen, sclerotic transformation of vascular walls and paravascular tissues. In the myocardium, the number density of neutrophils, the percentage of lymphocytes, and neutrophils become smaller, with a simultaneous increase in the relative numbers of erythrocytes and macrophages, and changes in the content of macrophages remained until the end of the observation—up to 10 days after the surgery. The discovered effect of MSC EVs is most likely associated with the suppression of the activity of the inflammatory process in the PCT area, which, in turn, was caused by a longer ingress of detritus with blood flow into the myocardium. The absence of statistically significant differences between changes in the myocardium of the left and right ventricles may indicate that both detritus from the surgical site and MSC EVs affect the heart spreading through the coronary artery system.

20 February 2019 in Novosti Khirurgii
Verified
Journal Article
Open access
IMInstitute of Chemical Biology and Fundamental Medicine
Institute of Chemical Biology and Fundamental Medicine
IMIgor Maiborodin
Igor Maiborodin
NFN.F. Figurenko
N.F. Figurenko
AEA.A. Elovskiy
A.A. Elovskiy
M“Medical Center “Avicenna”
Medical Center “Avicenna”
ASAndrey Ivanovich Shevela
Andrey Ivanovich Shevela

10 February 2025 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Open access
PDF file
IMIgor Maiborodin
Igor Maiborodin
ASA. O. Shumeikina
A. O. Shumeikina
VMV. I. Maiborodina
V. I. Maiborodina
СКС. Э. Красильников
С. Э. Красильников
An analysis of the literature for 2022 was carried out in order to study the latest data on the cardiotoxicity of antitumor drugs. The abundance of data on the pathogenesis of cardiotoxicity of even a single chemotherapeutic agent indicates the multifactorial effect and the characteristics of the individual sensitivity of each patient to a particular drug. Due to the multifactorial nature of the pathogenesis of cardiotoxicity, the clinical manifestations of this complication are also numerous. It should be taken into account that oncological patients could have suffered from various cardiovascular diseases even before tumor development, and that cancer progression even without therapeutic intervention, or before it, can cause cardiac side effects. To identify such processes, it is necessary to monitor cardio-oncological patients in dynamics. When conducting conservative cancer treatment and in the event of the development of side effects, the complete cancellation of treatment is impossible, as it is necessary to continue the therapy, as well as repeat its courses, often throughout the patient's life. In this regard, methods are needed to reduce the severity of the cardiotoxic effect, as well as suppress the adverse effects of anticancer drugs on the myocardium, and the search and development of effective methods for the prevention and treatment of cardiotoxicity of chemotherapy drugs are still relevant. Timely detection, and hence, prevention, as well as reduction of the degree of damaging effects of the beginning cardiotoxic effect when using cancer chemotherapy agents is possible only with close cooperation between oncologists and cardiologists.